Cap

Zacks Small Cap Research – NVX: Positive Takeaways From Analyst Day Include Company’s Successful Attainment of 2024 Key Objectives – Go Health Pro

by
Zacks Small Cap Research – NVX: Positive Takeaways From Analyst Day Include Company’s Successful Attainment of 2024 Key Objectives – Go Health Pro

By M. Marin NASDAQ:NVX READ THE FULL NVX RESEARCH REPORT NVX has successfully attained four key objectives, including securing upfront demand & funding Novonix (NASDAQ:NVX) hosted an Investor Day last week that we attended virtually. As the company contributes to the development of a North American-based supply chain to support the battery and clean energy … Read more

Zacks Small Cap Research – MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… – Go Health Pro

by

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Encouraging Interim Results from Phase 2b/3 COMBAT-ALS Trial On December 5, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a poster presentation at the 35th International Symposium on ALS/MND would feature a study update and interim analysis results from the ongoing Phase 2b/3 COMBAT-ALS trial … Read more

Zacks Small Cap Research – SWP.TO: Industry Outlook Shows Expected Catalysts for Swiss Water Growth Continuing – Go Health Pro

by
Zacks Small Cap Research – SWP.TO: Industry Outlook Shows Expected Catalysts for Swiss Water Growth Continuing – Go Health Pro

By M. Marin OTC:SWSSF | TSX:SWP.TO READ THE FULL SWP.TO RESEARCH REPORT Rising consumption of ‘decaf’ & specialty coffees important are growth drivers that are expected to continue… British Columbia-based Swiss Water Decaffeinated Coffee Inc. (OTC:SWSSF) (TSX:SWP.TO) is a leading specialty coffee company and premium green coffee decaffeinator focused on producing chemical-free decaffeinated coffee. The … Read more

Zacks Small Cap Research – LEXX: Phase I Start Imminent – Go Health Pro

by
Zacks Small Cap Research – LEXX: Phase I Start Imminent – Go Health Pro

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal third 2024 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the Phase Ib trial evaluating DehydraTECH in obese patients. Several new patents were granted bringing the total to 43. … Read more

Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

by
Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Planning Phase 3 Oral Insulin study under revised protocol, new CRO agreement in place Oramed Pharmaceuticals (NASDAQ:ORMP) has pivoted its clinical R&D focus to prioritize studying ORMD 0801 for subpopulations of patients with pooled specific parameters who responded well to oral insulin in its prior … Read more

x